Acadia Pharmaceuticals Inc.’s bigger-than-expected public offering grossed about $182 million that will fund ongoing efforts to expand the indications for pimavanserin, due to become the subject of a new drug application (NDA) in Parkinson’s disease psychosis (PDP) before the year is done.